GLP-1 side effects are the part people worry about most. You may want the medicine to help. You may also fear feeling sick every day.
The stories online do not help much. One person feels fine, while the next describes weeks of nausea. It is hard to know what is normal.
This page lays it out in plain terms. You will learn what is common, what is serious, and what to do. You will also learn the signs that mean calling your provider.
KEY TAKEAWAYS
- Most GLP-1 side effects involve the stomach, like nausea, and often ease as your body adjusts.
- In the Wegovy® label, nausea affected about 44% of adults, versus 16% on placebo.
- Serious effects are less common, such as pancreatitis, gallbladder problems, and kidney strain from dehydration.
- A boxed warning covers a rare thyroid tumor, so some people should not use these medicines.
- Starting low, going slow, and staying hydrated can make side effects easier to handle.
What readers want to figure out
- You want to know which GLP-1 side effects are normal and which are not.
- You want real numbers, not scary stories, about how common each effect is.
- You want simple steps to feel better while your body adjusts.
- You want to know the warning signs that mean you should get care.
- You want to understand the thyroid warning before you ask about these medicines.
Why GLP-1 medicines cause side effects
GLP-1 medicines copy a gut hormone your body makes after you eat. That hormone slows how fast your stomach empties. It also helps you feel full sooner.
This slowing is the whole point. It is also why most side effects hit the stomach. When food moves more slowly, you can feel queasy or full fast.
Most effects show up early, when you first start or raise the dose. They often fade over weeks as your body adjusts. That pattern is the key thing to remember.
The most common GLP-1 side effects
The most common side effects involve digestion. They include nausea, vomiting, diarrhea, constipation, belly pain, and tiredness. Nausea is the one people report most.
The numbers come from large trials and the FDA brand labels. In the STEP 1 trial of Wegovy® (N=1,961), nausea led the list. The Wegovy® label reports nausea in about 44% of adults, versus 16% on placebo.
Other Wegovy® effects follow the same pattern. The label lists diarrhea in about 30% of adults, vomiting in 24%, and constipation in 24%. Belly pain was about 20%, and tiredness about 11%.
Zepbound® looks similar in its own trials. In SURMOUNT-1 (N=2,539), stomach effects led again. The Zepbound® label reports nausea in about 25% to 29% of adults, versus 8% on placebo.
The Zepbound® label lists diarrhea in about 19% to 23% and vomiting in 8% to 13%. Constipation ran about 11% to 17%. Most of these effects were mild or moderate.
Here is the reassuring part. In STEP 1, only about 4.5% of the Wegovy® group stopped for stomach effects, versus 0.8% on placebo. Most people kept going as the feelings eased.
Most GLP-1 side effects are stomach related, show up early, and ease over weeks as your body adjusts.
GLP-1 side effects at a glance
The table below sums up the common effects. It shows how often each one shows up and a simple step that may help. Your own plan always comes from your prescriber.
| Side effect | How common (brand label) | What may help |
|---|---|---|
| Nausea | About 44% Wegovy®; 25% to 29% Zepbound® | Smaller, blander meals; eat slowly; stop when full |
| Diarrhea | About 30% Wegovy®; 19% to 23% Zepbound® | Sip water often; add gentle, low-fat foods |
| Vomiting | About 24% Wegovy®; 8% to 13% Zepbound® | Small sips of fluid; call your provider if it lasts |
| Constipation | About 24% Wegovy®; 11% to 17% Zepbound® | Fluids, fiber, and daily movement |
| Belly pain | About 20% Wegovy®; 9% to 10% Zepbound® | Track it, and report severe or lasting pain |
| Tiredness | About 11% Wegovy®; 5% to 7% Zepbound® | Rest, fluids, and steady meals and sleep |
Figures are from the FDA labels for Wegovy® and Zepbound®, based on the STEP and SURMOUNT trials. These numbers apply to the branded products only. Full sources appear below.
A few other effects people ask about
A few milder effects round out the list. Burping and reflux can show up, since the stomach empties slowly. Both are noted on the Zepbound® label.
Shots can also cause minor skin reactions. The Zepbound® label lists injection site reactions in about 6% to 8% of adults. Rotating the spot each week can help.
A small rise in heart rate is possible too. The Wegovy® label reports a mean increase of about 1 to 4 beats per minute. Your prescriber can keep an eye on it.
Serious side effects to know about
Serious side effects are far less common. Still, it helps to know the names and the signs. The FDA labels list each one.
Acute pancreatitis means the pancreas becomes inflamed. Both the Wegovy® and Zepbound® labels report it. The main sign is severe belly pain that may spread to your back.
Gallbladder problems can also happen, including gallstones. Both brand labels note acute gallbladder disease. Sharp pain in the upper right belly is a warning sign.
Dehydration can strain the kidneys. Hard vomiting or diarrhea can leave you low on fluids. Both labels report acute kidney injury, and some cases needed dialysis.
Low blood sugar is a risk in certain cases. The Wegovy® label notes higher risk when the medicine is used with insulin or a sulfonylurea. Your prescriber may adjust those other medicines.
A blocked intestine, called ileus, has also been reported. The FDA added ileus to the Ozempic® (semaglutide) label in 2023. Signs include belly swelling, no gas or stool, and vomiting.
One more risk involves surgery. GLP-1 medicines slow the stomach, so food can stay longer than expected. That can raise the risk of breathing food into the lungs during anesthesia.
Tell any surgeon or anesthesia team that you take a GLP-1. In 2024, the FDA added this caution to the labels. Recent expert guidance says most people can keep taking their medicine, but your team decides.
When to call your provider or seek care
Most side effects are mild and pass with time. A few signs, though, mean you should reach out fast. Call your provider or seek care if you notice these.
- Severe or lasting belly pain, especially pain that spreads to your back.
- Vomiting or diarrhea that will not stop, or signs of dehydration like dizziness.
- Sharp pain in the upper right belly, fever, or yellowing skin.
- Shakiness, sweating, or confusion, which can signal low blood sugar.
- Belly swelling with no gas or stool, which can signal a blockage.
- A neck lump, trouble swallowing, or a hoarse voice that does not go away.
This list is not complete, and it is not medical advice. When in doubt, ask your prescriber. They know your full history.
When belly pain is severe or will not ease, do not wait it out. That is the moment to call your provider.
What you can do to feel better
Small habits can make a big difference. Most focus on the stomach, since that is where effects land. Your prescriber can tailor these to you.
Start low and go slow. Doses usually rise in small steps over weeks. This slow climb, called titration, is the top way to limit nausea.
Change how you eat. Smaller meals help, and so does eating slowly. Stop when you feel full, and lean on blander, lower-fat foods on rough days.
Stay hydrated. Sip water through the day, even when you are not thirsty. Good hydration also helps protect your kidneys if your stomach is upset.
Mind the timing. Some people take their weekly shot before a lighter, calmer day. For constipation, fiber, fluids, and a daily walk can help things move.
Does feeling sick mean it is working?
This is a common worry, and the answer is no. Nausea is not a sign of how well the medicine works. Some people feel very little and still do well.
You do not need to feel sick to benefit. If side effects are rough, that is a reason to talk with your prescriber, not to push through. A steady, comfortable plan is the goal.
The boxed warning: thyroid C-cell tumors
GLP-1 brands carry the FDA’s strongest warning, called a boxed warning. It describes a rare thyroid tumor seen in animal studies. In rodents, these medicines caused thyroid C-cell tumors.
It is not known whether they cause these tumors in people. Still, the warning sets a firm rule. Some people should not use these medicines at all.
Do not use Wegovy®, Zepbound®, or related brands if you have a personal or family history of medullary thyroid carcinoma. The same holds for a rare condition called MEN 2. Your prescriber will ask about this first.
How side effects are managed over time
Side effects are managed with your prescriber, not alone. They track how you feel and adjust the plan. That may mean holding a dose steady or slowing the climb.
Regular check-ins are part of the process. You can report what is hard, and they can suggest fixes. peptides.io shares education, not medical advice.
Where you get care can shape this support. Some programs offer closer follow-up and more titration help. The next step below can help you compare your options.
The Bottom line
GLP-1 side effects are mostly about the stomach. Nausea, diarrhea, and constipation are common, and they often ease with time. Starting low and going slow makes them easier.
Serious effects are rarer but real. Pancreatitis, gallbladder problems, kidney strain, and the thyroid boxed warning all deserve attention. Severe or lasting belly pain is a signal to get care.
You do not have to sort this out alone. Your prescriber manages the plan, and the guide below helps you compare where to get support.
FREQUENTLY ASKED QUESTIONS
The most common GLP-1 side effects involve the stomach. Nausea leads the list, followed by diarrhea, vomiting, constipation, belly pain, and tiredness. In the Wegovy® label, nausea affected about 44% of adults, versus 16% on placebo. Most effects are mild, show up early, and ease over weeks as your body adjusts to the medicine.
For most people, the worst side effects are early and short. They tend to appear when you start or raise the dose. As your body adjusts over days to weeks, nausea and other stomach effects often fade. Raising the dose slowly helps. If an effect stays strong or gets worse, tell your prescriber, since your plan may need a change.
A few habits often help. Eat smaller meals, go slowly, and stop when you feel full. Choose blander, lower-fat foods on rough days, and sip water through the day. A slow dose increase, guided by your prescriber, is the single best way to limit nausea. If nausea is severe, your prescriber can adjust the plan for you.
Serious effects are less common but important. The FDA labels list acute pancreatitis, gallbladder problems, and kidney injury from dehydration. Low blood sugar is a risk with insulin or a sulfonylurea. A blocked intestine, called ileus, has also been reported. Severe or lasting belly pain is a key warning sign, so seek care if it happens.
They are very similar. Both are GLP-1 based medicines, and both cause mostly stomach effects like nausea and diarrhea. In their labels, nausea ran about 44% for Wegovy® and about 25% to 29% for Zepbound®. Both also carry the same boxed warning about thyroid tumors. Your prescriber can explain how each brand may fit you.
Some people notice hair thinning or a more drawn face. These are usually tied to fast weight loss, not the medicine itself. The Zepbound® label does list hair loss in a small share of adults. Hair often recovers as weight stabilizes. If it worries you, your prescriber can check for other causes, like low iron.
Do not decide alone. Tell your surgeon and anesthesia team that you take a GLP-1 well before any procedure. These medicines slow the stomach, which can raise the risk of breathing in food during anesthesia. In 2024, the FDA added this caution to the labels. Your care team will tell you whether to pause a dose.
KEEP READING
Where to get GLP-1 care: our provider comparison
Side effects are easier with good support. See how the leading GLP-1 programs compare on titration help, follow-up, pharmacy model, and state coverage.
→ Read next: /compare/best-glp1-programs/
SOURCES
1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. US Food and Drug Administration. WEGOVY (semaglutide) injection: Prescribing Information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
4. US Food and Drug Administration. ZEPBOUND (tirzepatide) injection: Prescribing Information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf
5. US Food and Drug Administration. OZEMPIC (semaglutide) injection: Prescribing Information (ileus added, postmarketing). 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
6. American Society of Anesthesiologists, et al. Multisociety guidance: most patients can continue GLP-1 drugs before surgery. 2024. https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance
Last updated: 2026-07-10 · Editorially reviewed by the Peptides.io team
Comments